<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36146882</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Comment on Hietanen et al. Cytolytic Properties and Genome Analysis of Rigvir<sup>®</sup> Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates. <i>Viruses</i> 2022, <i>14</i>, 525.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2076</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v14092076</ELocationID><Abstract><AbstractText>In a recent article published in <i>Viruses</i> by Hietanen et al. [...].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alberts</LastName><ForeName>Pēteris</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9585-9288</Identifier><AffiliationInfo><Affiliation>Rigvir, Atlasa iela 7C, LV-1026 Riga, Latvia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Viruses. 2022 Mar 04;14(3):525. doi: 10.3390/v14030525</RefSource><PMID Version="1">35336934</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Viruses. 2022 Sep 19;14(9):2078. doi: 10.3390/v14092078</RefSource><PMID Version="1">36146884</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050130" MajorTopicYN="Y">Oncolytic Virotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The author is an employee of Rigvir.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>1</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36146882</ArticleId><ArticleId IdType="pmc">PMC9506255</ArticleId><ArticleId IdType="doi">10.3390/v14092076</ArticleId><ArticleId IdType="pii">v14092076</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hietanen E., Koivu M.K.A., Susi P. Cytolytic properties and genome analysis of Rigvir® oncolytic virotherapy virus and other Echovirus 7 isolates. Viruses. 2022;14:525. doi: 10.3390/v14030525.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14030525</ArticleId><ArticleId IdType="pmc">PMC8949920</ArticleId><ArticleId IdType="pubmed">35336934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietanen E., Smura T., Hakanen M., Chansaenroj J., Merilahti P., Nevalainen J., Pandey S., Koskinen S., Tripathi L., Poovorawan Y., et al. Genome Sequences of RIGVIR Oncolytic Virotherapy Virus and Five Other Echovirus 7 Isolates. Genome Announc. 2018;6:7–8. doi: 10.1128/genomeA.00317-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/genomeA.00317-18</ArticleId><ArticleId IdType="pmc">PMC5920193</ArticleId><ArticleId IdType="pubmed">29700151</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilgase A., Patetko L., Blāķe I., Ramata-Stunda A., Borodušķis M., Alberts P. Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro. J. Cancer. 2018;9:1033–1049. doi: 10.7150/jca.23242.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.23242</ArticleId><ArticleId IdType="pmc">PMC5868171</ArticleId><ArticleId IdType="pubmed">29581783</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigvir Improves Control and Circulation of Medicines.  [(accessed on 15 September 2022)].  Available online:  https://www.rigvir.com/news/rigvir-improves-control-and-circulation-of-medicines.php.</Citation></Reference><Reference><Citation>Doniņa S., Strēle I., Proboka G., Auziņš J., Alberts P., Jonsson B., Venskus D., Muceniece A. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25:421–426. doi: 10.1097/CMR.0000000000000180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CMR.0000000000000180</ArticleId><ArticleId IdType="pmc">PMC4560272</ArticleId><ArticleId IdType="pubmed">26193376</ArticleId></ArticleIdList></Reference><Reference><Citation>Polania Gutierrez J.J., Munakomi S.  Intramuscular Injection. [Updated 9 February 2022] StatPearls Publishing; Treasure Island, FL, USA: 2022.  [(accessed on 17 March 2022)].  Available online:  www.ncbi.nlm.nih.gov/books/NBK556121.</Citation><ArticleIdList><ArticleId IdType="pubmed">32310581</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberts P., Tilgase A., Rasa A., Bandere K., Venskus D. The advent of oncolytic virotherapy in oncology: The Rigvir® story. Eur. J. Pharmacol. 2018;837:117–126. doi: 10.1016/j.ejphar.2018.08.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2018.08.042</ArticleId><ArticleId IdType="pubmed">30179611</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilgase A., Grīne L., Blāķe I., Borodušķis M., Rasa A., Alberts P. Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines. BMC Res. Notes. 2020;13:222. doi: 10.1186/s13104-020-05068-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-020-05068-4</ArticleId><ArticleId IdType="pmc">PMC7164219</ArticleId><ArticleId IdType="pubmed">32299493</ArticleId></ArticleIdList></Reference><Reference><Citation>Piwoni K., Jaeckel G., Rasa A., Alberts P. 4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 virus Rigvir administered intramuscularly with a 4-week recovery period. Toxicol. Rep. 2021;8:230–238. doi: 10.1016/j.toxrep.2021.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxrep.2021.01.009</ArticleId><ArticleId IdType="pmc">PMC7840795</ArticleId><ArticleId IdType="pubmed">33537211</ArticleId></ArticleIdList></Reference><Reference><Citation>The Centers for Disease Control and Prevention (CDC), Laboratory Procedure Manual, Method 2101.01, Revised April 30, 2015.  [(accessed on 10 March 2022)]; Available online:  https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/VOCMWB_E_met_Trihalomethanes_MTBE_Nitromethane.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>